All Stories

  1. Inflammation and LDL Reduction

    Article • Current Vascular Pharmacology, January 2023, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros, GEORGIOS SFIKAS

  2. Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments

    Article • Current Vascular Pharmacology, November 2021, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  3. Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives

    Article • Current Vascular Pharmacology, December 2020, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  4. Prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?

    Article • Current Vascular Pharmacology, October 2020, Bentham Science Publishers

    Konstantinos Imprialos, Professor Vasilios Gabriel Athyros, GEORGIOS SFIKAS

  5. Dysmetabolic Iron Overload in Metabolic Syndrome

    Article • Current Pharmaceutical Design, April 2020, Bentham Science Publishers

    Konstantinos Imprialos, Professor Vasilios Gabriel Athyros, Konstantinos Stavropoulos

  6. Hypertension in Metabolic Syndrome: Novel Insights

    Article • Current Hypertension Reviews, February 2020, Bentham Science Publishers

    Konstantinos Imprialos, Konstantinos Stavropoulos, Professor Vasilios Gabriel Athyros

  7. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block

    Article • Current Vascular Pharmacology, January 2020, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  8. Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice

    Article • Current Vascular Pharmacology, January 2020, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  9. Pharmacological Management of Type 2 Diabetes Complications

    Article • Current Vascular Pharmacology, January 2020, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  10. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?

    Article • Current Vascular Pharmacology, December 2019, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  11. Statin use in patients with diabetes: one drug, multiple benefits

    Article • Expert Review of Cardiovascular Therapy, August 2019, Taylor & Francis

    Kalliopi Kotsa, Professor Vasilios Gabriel Athyros

  12. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia

    Article • Current Pharmaceutical Design, April 2019, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros, Alexia Piperidou

  13. Understanding the cardiovascular risk with non-insulin antidiabetic drugs

    Article • Expert Opinion on Drug Safety, March 2019, Taylor & Francis

    Konstantinos Imprialos, Professor Vasilios Gabriel Athyros, Konstantinos Stavropoulos

  14. Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment

    Article • Current Medical Research and Opinion, March 2019, Taylor & Francis

    Professor Vasilios Gabriel Athyros

  15. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease

    Article • Current Pharmaceutical Design, February 2019, Bentham Science Publishers

    Konstantinos Imprialos, Konstantinos Stavropoulos, Professor Vasilios Gabriel Athyros

  16. SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature

    Article • Current Clinical Pharmacology, January 2019, Bentham Science Publishers

    Konstantinos Imprialos, Konstantinos Stavropoulos, Professor Vasilios Gabriel Athyros

  17. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation

    Article • Current Pharmaceutical Design, January 2019, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  18. Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia

    Article • Current Pharmaceutical Design, January 2019, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  19. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints

    Article • Current Pharmaceutical Design, September 2018, Bentham Science Publishers

    Konstantinos Imprialos, Konstantinos Stavropoulos, Professor Vasilios Gabriel Athyros

  20. Statins and substantially increased ALT values at baseline

    Article • Cardiovascular Therapeutics, June 2018, Wiley

    Professor Vasilios Gabriel Athyros

  21. Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension

    Article • Current Vascular Pharmacology, May 2018, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros, Prof Vasilios Kotsis

  22. Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?

    Article • The Open Cardiovascular Medicine Journal, March 2018, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  23. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk

    Article • Current Vascular Pharmacology, March 2018, Bentham Science Publishers

    Konstantinos Imprialos, Professor Vasilios Gabriel Athyros

  24. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?

    Article • Current Vascular Pharmacology, March 2018, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  25. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications

    Article • Current Vascular Pharmacology, March 2018, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  26. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?

    Article • Current Vascular Pharmacology, March 2018, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  27. What is the role of statins in the elderly population?

    Article • Expert Review of Clinical Pharmacology, February 2018, Taylor & Francis

    Konstantinos Imprialos, Konstantinos Stavropoulos, Professor Vasilios Gabriel Athyros

  28. The potential role of statins in treating liver disease

    Article • Expert Review of Gastroenterology & Hepatology, February 2018, Taylor & Francis

    Konstantinos Imprialos, Konstantinos Stavropoulos, Professor Vasilios Gabriel Athyros

  29. Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?

    Article • Journal of Clinical Hypertension, February 2018, Wiley

    Konstantinos Imprialos, Konstantinos Stavropoulos, Professor Vasilios Gabriel Athyros

  30. Letter: statins and cirrhosis

    Article • Alimentary Pharmacology & Therapeutics, November 2017, Wiley

    Professor Vasilios Gabriel Athyros

  31. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins

    Article • Current Pharmaceutical Design, May 2017, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  32. Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?

    Article • The Open Hypertension Journal, April 2017, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  33. Exploring the Management of Statin Intolerant Patients: 2016 and Beyond

    Article • Current Vascular Pharmacology, October 2016, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  34. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER...

    Article • Current Vascular Pharmacology, October 2016, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  35. Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?

    Article • Current Vascular Pharmacology, November 2015, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  36. Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment

    Article • Current Vascular Pharmacology, October 2015, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  37. Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A

    Article • Current Vascular Pharmacology, October 2015, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  38. Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?

    Article • Current Vascular Pharmacology, July 2015, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  39. Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease

    Article • Current Vascular Pharmacology, July 2015, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  40. Editorial: Effect of Statins on Rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy

    Article • Current Vascular Pharmacology, May 2015, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  41. Editorial: (Persistent Elevation of Blood Pressure in Children and Adolescents is Associated with Arterial Hypertension and Premature Atherosclerosis in Adults. Is it Possible to Reverse this?)

    Article • Current Vascular Pharmacology, December 2014, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  42. Hyperuricemia as a risk factor for cardiovascular disease

    Article • Expert Review of Cardiovascular Therapy, November 2014, Taylor & Francis

    Professor Vasilios Gabriel Athyros

  43. Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!

    Article • Current Medical Research and Opinion, September 2014, Informa Healthcare

    Professor Vasilios Gabriel Athyros

  44. Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview

    Article • Current Vascular Pharmacology, July 2014, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  45. Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters

    Article • The Open Cardiovascular Medicine Journal, September 2012, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  46. EDITORIAL - Is There a Role for Hypolipidaemic Drug Therapy in the Prevention or Treatment of Microvascular Complications of Diabetes?

    Article • The Open Cardiovascular Medicine Journal, March 2012, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  47. Editorial: Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?

    Article • The Open Cardiovascular Medicine Journal, December 2011, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  48. Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment

    Article • The Open Cardiovascular Medicine Journal, February 2011, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros

  49. Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients

    Article • The Open Cardiovascular Medicine Journal, December 2007, Bentham Science Publishers

    Professor Vasilios Gabriel Athyros